Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

Model scores of the 29,894 trials active now.

Model score 34% for any early termination, 21% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-07-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chronic kidneykidney diseasecancerhemodialysisheart
  Phrases that lowered it: diseaseshivdrugsresistancediabetes
• Sponsor's past termination rate: 18.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 50% (lowers risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 109 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 9.1% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 392 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: double (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 3 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer NCT01325311 · started 2011 · scored riskier than 82% of active trials completed
• Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness NCT01036321 · started 2009 · scored riskier than 95% of active trials completed
• Metformin Prostate Cancer Adjuvant Trial NCT02176161 · started 2014 · scored riskier than 97% of active trials completed
• Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome NCT01077479 · started 2010 · scored riskier than 70% of active trials completed
• Metformin in Castration-Resistant Prostate Cancer NCT01215032 · started 2010 · scored riskier than 39% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.